This paper is marked retracted in the scholarly record (OpenAlex). Interpret its findings with caution.
Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer Treatment and Pharmacology · HER2/EGFR in Cancer Research · Lung Cancer Treatments and Mutations
Following publication, significant concerns were raised regarding the integrity of the patient data and reporting within the manuscript. An investigation was conducted in accordance with Frontiers’ policies, and it was determined that the conclusions and assertions were not sufficiently supported by the findings from the material provided; therefore, the article has been retracted.
This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.